Atrium Therapeutics (RNA) Income Statement (2025 - 2026)
Quarterly Income Statement report data from Mar 31, 2025 to Mar 31, 2026 for Atrium Therapeutics (RNA).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Mar 31, 2025 | |
|---|---|---|
Revenue and COGS | ||
Total Revenue | 20M (+1150.96%) | 1.57M |
Operating Expenses | ||
Research And Development | 17M (+140.06%) | 6.94M |
Selling General And Administrative | 20M (+869.38%) | 2.09M |
Operating Expenses | 37M (+308.86%) | 9.03M |
Depreciation And Amortization | 150K (+200.00%) | 50K |
Operating Income | ||
Operating Income | -17.28M (+131.95%) | -7.45M |
Ebit | -17.28M (+131.95%) | -7.45M |
EBITDA | -17.13M (+131.49%) | -7.40M |
Other Income / Expenses | ||
Other Non Operating Income | 650K | - |
Net Income | ||
Net Income From Continuing Operations | -16.63M (+123.22%) | -7.45M |
Net Income | -16.63M (+123.22%) | -7.45M |